BioElectronics’ ActiPatch® Actual-Use Survey Finds 90% Have Excellent Chronic Pain Management and 88% had a Decrease in Opioid Use

BioElectronics’ ActiPatch® Actual-Use Survey Finds 90% Have Excellent Chronic Pain Management and 88% had a Decrease in Opioid Use

  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest

ActiPatch Reduction in Medication UseFREDERICK, MD, USA, February 4, 2015– BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today released analysis of its ongoing and second long term follow up survey of customers in the United Kingdom and Ireland who are managing chronic pain with ActiPatch® Therapy, and reducing their dependence on systemic pain drugs.  The study of more than 1,300 consumers looked at their chronic pain management, quality of life, pain medication use, and purchasing extent of ActiPatch®.

“The consumer responses confirm that ActiPatch® Therapy is a well-accepted chronic pain therapy that has a significant and meaningful impact on the user’s severe chronic pain levels and quality of life.,” said Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics Corporation.  “One important aspect of this level of pain reduction is that a majority of ActiPatch® users are reporting a marked decrease in systemic analgesic pain medication use including reductions in opioid based analgesics.”

Overall, the follow up survey found that ActiPatch® is being well accepted and that a high percent of consumers who have used the 7- Day ActiPatch® sample are moving onto a purchase of the commercial ActiPatch® device.

Key user findings:

  • 90% reported long lasting 50% pain reduction.
  • 85% indicated a moderate to great improvement of their quality of life.
  • 85% indicated reduction in the use of pain medications.
  • Of those taking opioids pain drugs alone, 76% reported a moderate to complete elimination of their use.

 

ActiPatch® Therapy devices are readily available over-the-counter outside of the US for approximately $30.00 retail, or $0.04 per hour of therapy. Visit www.bielcorp.com/clinical-evidence/musculoskeletal-pain to see more detailed consumer responses and www.facebook.com/ActiPatch to view what people in the UK and Ireland are saying about the products.

 

About BioElectronics Corporation
BioElectronics Corporation is a leader in Bioelectronics and the maker of a family of disposable, drug-free, medical devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses.  For more information, please visit www.bielcorp.com.

Contact: Paul Knopick: 940.262.3584
pknopick@eandecommunications.com